Benjamin Hohl Sells 900 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 900 shares of the stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.15, for a total value of $74,202.50.
• On Wednesday, November 27th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50.
• On Monday, October 28th, Benjamin Hohl sold 6,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.56, for a total value of $178,500.00.
• On Friday, October 18th, Benjamin Hohl sold 814 shares of Enliven Therapeutics stock. The stock was sold at an average price of $30.00, for a total transaction of $24,420.00.
• On Friday, October 4th, Benjamin Hohl sold 10,218 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.51, for a total transaction of $281,097.18.
• On Monday, October 7th, Benjamin Hohl sold 1,270 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total value of $34,937.70.

Enliven Therapeutics Trading Up 6.2 %

Shares of ELVN opened at $23.90 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $10.90 and a twelve month high of $30.03. The firm has a market capitalization of $1.17 billion, a P/E ratio of -12.58 and a beta of 1.02. The firm’s 50-day moving average is $25.09 and its two-hundred day moving average is $24.28.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Lord Abbett & CO. LLC acquired a new position in Enliven Therapeutics during the third quarter worth $8,199,000. Franklin Resources Inc. acquired a new position in shares of Enliven Therapeutics during the 3rd quarter worth $559,000. Barclays PLC boosted its position in shares of Enliven Therapeutics by 295.8% in the 3rd quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after buying an additional 42,012 shares in the last quarter. Geode Capital Management LLC increased its holdings in Enliven Therapeutics by 9.9% during the 3rd quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock valued at $19,164,000 after acquiring an additional 67,813 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Enliven Therapeutics by 107.0% during the third quarter. Wellington Management Group LLP now owns 70,170 shares of the company’s stock worth $1,792,000 after acquiring an additional 36,267 shares during the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on ELVN shares. HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st. Robert W. Baird boosted their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. Finally, BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They set a “buy” rating and a $42.00 price objective for the company. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $38.25.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.